Under the agreement, Cellares will use its Cell Shuttle and Cell Q systems to automate TSC-101 manufacturing processes.
CDMO and multimodal biosafety testing organization, today announced the enhancement of its dedicated GMP cell banking suites ...
Quality by design is critical for cell and gene therapy manufacturing where process controls directly influence product ...
Chimeric antigen receptor (CAR) -T-cell therapies have yielded remarkable results in the treatment of hematological malignancies. Several autologous CAR T-cell products have received marketing ...
Researchers from the Critical Analytics for Manufacturing Personalized Medicine (CAMP), an interdisciplinary research group (IRG) of Singapore-MIT Alliance for Research and Technology (SMART), in ...
Realize safe, scalable, and compliant cell therapies by building analytical strategies that exceed regulatory expectations.
Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing facility will be ...
Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results